← Russell 3000 cross-section

IRWD IRONWOOD PHARMACEUTICALS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$701m
Revenue TTM
$389m
Net income TTM
$130m
Free cash flow
Composite score
Sector rank
#2226

Valuation

P / E
5.4
EV / EBITDA
2.6
EV / sales
1.6
FCF yield
Earnings yield vs 10-yr
13.81pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
33.4%
EBITDA margin
60.6%
ROE
-80.2%
ROIC
Revenue growth
26.2%

Insider activity, last 90 days

Net open-market
$-0.66m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Our revenues are generated primarily through our collaborative arrangements and license agreements related to research and development and commercialization of linaclotide. ​ The majority of our revenues are generated from the sales of LINZESS in the U.S. Although we expect net sales to increase over time, the settlement payments between AbbVie and us, resulting in collaborative arrangements revenue or collaboration expense, are subject to fluctuation based on the ratio of selling, general and administrative expenses incurred by each party. …IRONWOOD PHARMACEUTICALS INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →